Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2260 participants.

Also called NCT05410925

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,260 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05410925
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05410925. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-08 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
Acronym
OPTIMA-6
Condition
ST Elevation Myocardial Infarction
Intervention (Drug)
Recombinant staphylokinase
Intervention (Drug)
Placebo
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct05410925
Content hash
258d6491c170df5d4c6981b086c1b7cd334be91a7d0c0d754d1f9a66e473a180